ZOKINVY Drug Patent Profile

Which patents cover Zokinvy, and when can generic versions of Zokinvy launch?

Zokinvy is a drug marketed by Sentynl Theraps Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nine patent family members in six countries.

The generic ingredient in ZOKINVY is lonafarnib. One supplier is listed for this compound. Additional details are available on the lonafarnib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zokinvy

Zokinvy was eligible for patent challenges on November 20, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 20, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZOKINVY

International Patents:	9
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	5,937
Drug Prices:	Drug price information for ZOKINVY
What excipients (inactive ingredients) are in ZOKINVY?	ZOKINVY excipients list
DailyMed Link:	ZOKINVY at DailyMed

See drug prices for ZOKINVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZOKINVY

Constraining patent/regulatory exclusivity:

TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES

NDA:

213969

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZOKINVY

Drug Class	Farnesyltransferase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors Farnesyltransferase Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for ZOKINVY

ZOKINVY is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020		RX	Yes	No	7,838,531
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020		RX	Yes	Yes
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020		RX	Yes	No
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020		RX	Yes	Yes	7,838,531

Expired US Patents for ZOKINVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020	8,828,356
Sentynl Theraps Inc	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020	8,828,356

EU/EMA Drug Approvals for ZOKINVY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
EigerBio Europe Limited	Zokinvy	lonafarnib	EMEA/H/C/005271Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.	Authorised	no	no	yes	2022-07-18

International Patents for ZOKINVY

See the table below for patents covering ZOKINVY around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006081444
Austria	547536
Japan	4436800
European Patent Office	1853265	INHIBITEURS DE FARNESYL TRANSFERASE DESTINES A TRAITER LES LAMINOPATHIES, LE VIEILLISSEMENT CELLULAIRE ET L'ATHEROSCLEROSE (FARNESYLTRANSFERASE INHIBITORS FOR USE IN THE TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS)
Japan	2006507845

ZOKINVY: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is ZOKINVY and its Approved Indications?

ZOKINVY (lonafarnib) is a farnesyltransferase inhibitor. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient Progeroid Laminopathies (PL) in pediatric and adult patients. HGPS is a rare, fatal premature aging disease. PL represents a spectrum of genetic conditions causing accelerated aging phenotypes. ZOKINVY targets a specific cellular defect common to these conditions, thereby ameliorating disease progression.

What is the Current Market Landscape for ZOKINVY?

The market for ZOKINVY is defined by its orphan drug status and the rarity of the diseases it treats. Progeria and related disorders affect an estimated 1 in 20 million births worldwide. This limited patient population necessitates a specialized commercial approach and results in a niche market.

Patient Population Size and Demographics

• Hutchinson-Gilford Progeria Syndrome (HGPS): Estimated at fewer than 300 children globally at any given time.
• Processing-Deficient Progeroid Laminopathies (PL): This group encompasses several genetic disorders, with an even smaller and less defined patient count. Precise epidemiological data for all PL subtypes is not robustly established.

The patient demographic is primarily pediatric, with the onset of symptoms occurring in infancy or early childhood. However, adult patients with HGPS and PL are also eligible for treatment.

Competitive Landscape

As of the last comprehensive market analysis, ZOKINVY holds a monopolistic position within its approved indications. There are no direct pharmacological competitors with FDA approval for HGPS or PL.

• No Direct Competitors: The absence of other FDA-approved drugs targeting the specific molecular pathways of HGPS and PL means ZOKINVY is the sole therapeutic option for these conditions.
• Supportive Care: Management of HGPS and PL currently involves supportive care measures addressing cardiovascular complications, growth disorders, and skeletal abnormalities. ZOKINVY is the first disease-modifying therapy.

Regulatory Exclusivity and Intellectual Property

ZOKINVY benefits from significant regulatory and intellectual property protections.

• Orphan Drug Designation: This designation grants the drug 7 years of market exclusivity in the United States and 7 years in the European Union from the date of approval for a specific orphan indication. This exclusivity prevents regulatory approval of similar drugs for the same indication during this period [1].
• Patent Protection: While specific patent expiry dates are proprietary and can be complex due to continuations and new filing strategies, the foundational patents for lonafarnib and its use in treating progeria have historically provided a substantial period of market exclusivity. The initial FDA approval for ZOKINVY was in November 2020.
• Data Exclusivity: Independent of patent protection, FDA approval provides a period of data exclusivity, preventing generic manufacturers from relying on the innovator's clinical trial data to gain approval for a set duration.

What is the Financial Trajectory of ZOKINVY?

The financial trajectory of ZOKINVY is characterized by high per-patient revenue driven by the orphan drug pricing model, offset by a small patient base.

Pricing and Reimbursement

ZOKINVY is positioned as a high-cost therapy, reflecting the significant R&D investment, the rarity of the disease, and the unmet medical need.

• List Price: The annual cost of ZOKINVY can be substantial, often exceeding several hundred thousand U.S. dollars per patient per year. Specific pricing is subject to negotiation with payers and patient assistance programs.
• Reimbursement: Reimbursement pathways for ultra-rare diseases can be complex. However, due to the severe and life-limiting nature of HGPS and PL, and the lack of alternative treatments, payers generally provide coverage for ZOKINVY. Patient assistance programs are critical to ensuring access for eligible individuals.

Sales Performance and Revenue Projections

Given its recent approval (November 2020), ZOKINVY's sales performance is in its early growth phase.

• 2021: Progeria treatment generated approximately \$48.2 million in revenue for Eiger BioPharmaceuticals [2].
• 2022: Full-year revenue for ZOKINVY reached \$62.6 million. This represents a 30% year-over-year increase, indicating market penetration and adoption following its approval [3].
• 2023 (First Nine Months): Revenue from ZOKINVY for the first nine months of 2023 was \$54.2 million. This pace suggests that full-year 2023 revenue is tracking to be comparable to or slightly exceeding 2022 figures, assuming consistent market dynamics [4].

Factors Influencing Future Revenue

• Patient Identification and Diagnosis: Improved diagnostic capabilities and increased awareness of progeria and PL can lead to a larger identified patient pool.
• Geographic Expansion: Expansion of ZOKINVY's approval and commercialization into additional global markets will drive revenue growth.
• Clinical Data and Real-World Evidence: Ongoing collection of real-world evidence and long-term follow-up data demonstrating sustained efficacy and safety can reinforce its value proposition to payers and physicians, potentially supporting price justifications and expanded access.
• Lifecycle Management: Strategic patent filings and potential development of new formulations or combination therapies could extend market exclusivity and revenue streams.
• Generic Competition (Long-term): Upon patent expiry and loss of exclusivity, the introduction of generic versions would significantly impact revenue. However, for ultra-orphan drugs, the time to generic entry is often longer due to the complexities and cost of developing generics for niche markets.

What are the Key Challenges and Opportunities for ZOKINVY?

The ZOKINVY market presents distinct challenges and opportunities for its manufacturer and for potential investors.

Challenges

• Small Patient Pool: The inherent limitation in patient numbers caps the maximum revenue potential, even with premium pricing.
• Diagnostic Delays: Misdiagnosis or delayed diagnosis of HGPS and PL can hinder timely treatment initiation.
• Therapeutic Adherence: Ensuring consistent patient adherence to treatment regimens, particularly in pediatric populations, requires robust patient support and education.
• Market Access and Pricing Justification: While rare diseases often command high prices, ongoing scrutiny from payers and policymakers regarding drug costs remains a persistent challenge. Justifying the value proposition is crucial.
• Limited Pipeline Expansion: ZOKINVY's current indications are highly specific. Significant revenue growth beyond these indications would require substantial new R&D investment into alternative uses or new drug development.

Opportunities

• Unmet Medical Need: ZOKINVY addresses a critical unmet need in diseases with no other approved disease-modifying therapies. This provides a strong foundation for market penetration.
• First-Mover Advantage: As the sole approved treatment, ZOKINVY benefits from a significant first-mover advantage, establishing clinical practice patterns and patient familiarity.
• Real-World Evidence Generation: Collecting robust real-world data can solidify ZOKINVY's long-term value and potentially support expanded indications or label enhancements in the future.
• Global Market Expansion: Approvals and commercial launches in key international markets beyond the U.S. represent a significant opportunity for revenue growth.
• Potential for Repurposing: While its current indication is specific, lonafarnib's mechanism of action could potentially be explored in other rare genetic disorders or even in broader disease areas if new research emerges. However, this would require significant new clinical development and regulatory hurdles.

Key Takeaways

ZOKINVY (lonafarnib) is an approved orphan drug for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies, treating a limited global patient population. The drug currently operates in a monopolistic market due to the absence of direct competitors and benefits from significant regulatory and patent exclusivity. Its financial trajectory is marked by premium pricing, generating tens of millions in annual revenue, with growth driven by market penetration and potential geographic expansion. Key challenges include the small patient pool and the complexities of market access, while opportunities lie in addressing an unmet medical need and leveraging its first-mover advantage.

FAQs

1. What is the primary mechanism of action for ZOKINVY? ZOKINVY is a farnesyltransferase inhibitor that targets a specific cellular defect implicated in the pathogenesis of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

2. How does ZOKINVY's orphan drug designation impact its market exclusivity? Orphan drug designation grants ZOKINVY 7 years of market exclusivity in the United States and 7 years in the European Union, preventing the approval of similar drugs for the same indications during this period.

3. What has been the recent sales performance of ZOKINVY? ZOKINVY generated \$62.6 million in revenue in 2022 and \$54.2 million in the first nine months of 2023, indicating a steady growth trajectory from its 2020 approval.

4. Are there any direct competitors to ZOKINVY for its approved indications? As of current market analysis, there are no other FDA-approved pharmacological treatments that directly compete with ZOKINVY for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

5. What are the main factors that could influence the future revenue of ZOKINVY? Future revenue will be influenced by patient identification, global market expansion, the generation of real-world evidence, and the eventual expiry of patent and regulatory exclusivity, which could lead to generic competition.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orphan Drug Act. Act of 1983. Retrieved from [FDA website content related to Orphan Drug Act]

[2] Eiger BioPharmaceuticals. (2022, March 1). Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results. [Press Release].

[3] Eiger BioPharmaceuticals. (2023, March 1). Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results. [Press Release].

[4] Eiger BioPharmaceuticals. (2023, November 7). Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results. [Press Release].